|Mr. Peter Lynton Gunzburg B Comm, ASIA||Exec. Chairman & MD||75.28k||N/A||1952|
|Dr. Leearne Maree Hinch BSc., B.V.M.S., M.R.C.V.S., M.B.A.||Chief Exec. Officer||389.4k||N/A||N/A|
|Dr. Irmgard Irminger-Finger||Founder, Exec. Director & Chief Scientific Officer||150k||N/A||N/A|
|Ms. Pauline Anne Collinson||Company Sec.||N/A||N/A||N/A|
BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a screening test for the early detection of lung cancer in high-risk asymptomatic individuals; and BARD1 ovarian cancer test to detect ovarian cancer in high-risk women with a family history of breast/ovarian cancer or carrying BRCA1/2 mutations. The company has a collaboration with the Institute for Respiratory Health to evaluate a potential BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models. BARD1 Life Sciences Limited is based in South Perth, Australia.
BARD1 Life Sciences Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.